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ABSTRACT
Regulatory T cell (Treg) infusion for graft-versus-host disease treatment has been increasingly investigated. However, polyclonal Treg
may suppress the desired graft-versus-leukemia effect. Although allogeneic-specific (allo-specific) Treg may provide a more-targeted
graft-versus-host disease treatment, there is the need to develop easily translatable expansion protocols and to better characterize
their specificity and mechanisms of suppression. In this article, we provide a robust protocol for human allo-specific Treg expansion
and characterize their phenotype, potency, and specificity of suppression by testing different expansion conditions and suppression
assay milieus. We found that higher concentrations of IL-2 during expansion with allogeneic APC yielded allo-specific Treg that were
more-potent suppressors and displayed a more activated phenotype. Although responses to the same APC present during expansion
were the most suppressed, responses to third-party APC partially matched to the expansion APC were still significantly more
suppressed than responses to fully mismatched APC. Furthermore, suppression of responses to the expansion APC was strictly contact
dependent, whereas suppression of responses to mismatched APC was partially independent of contact. Finally, distinct subsets in
fresh and expanded Treg could be described using multidimensional visualization techniques. We propose that allo-specific Treg are
HLA specific and that the mechanisms of suppression elicited depend on their compatibility with the stimulators. ImmunoHorizons,
2021, 5: 307–321.
INTRODUCTION
Chronic graft-versus-host disease (cGvHD) is a major cause of
morbidity and non–relapse-related mortality in recipients of al-
logeneic hematopoietic stem cell transplantation (allo-HSCT)
(1). The standard treatment for cGvHD is steroid based and has
many side effects, with less than half of the patients achieving
a complete response (2). Because the frequencies and numbers
of regulatory T cells (Treg) have been shown to be reduced in
cGvHD patients (3–5), we (www.tregeneration.eu) and others
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(6–8) are currently performing clinical trials of polyclonal do-
nor Treg infusion in patients with steroid-resistant cGvHD. Al-
though preclinical studies in mice suggest that infusion of
polyclonal Treg can prevent cGvHD without compromising the
desirable graft-versus-leukemia (GVL) effect (9), their lack of
specificity still carries the risk of generalized immunosuppres-
sion. Allogeneic-specific (allo-specific) Treg have the potential
to provide a more-potent and targeted suppression than poly-
clonal Treg (10, 11). In mice, allo-specific Treg of known Ag
specificity have been shown to promote transplantation toler-
ance (12) and prevent graft-versus-host disease (GvHD), while
sparing GVL (13). In humans, Treg may need to suppress re-
sponses to a plethora of mostly unknown minor histocompati-
bility Ags reportedly involved in GvHD (14). Thus, expansion
of Treg with allogeneic APC will generate Treg specific for a
pool of allogeneic minor histocompatibility Ags, which ulti-
mately may provide a suitable solution for the treatment of
cGvHD without compromising GVL.
Treg have also been described as suitable for the pre-
vention of transplant rejection in solid organ transplanta-
tion, with demonstrated results in phase I clinical trials
involving kidney and liver transplantation (15). A recent
review by Atif et al. (16) lists the many current clinical tri-
als assessing the potential of Treg therapy in solid organ
transplantation while re-enforcing the advantages of Ag-
specific Treg. Hence, the characterization of expanded Ag-
specific Treg function and phenotype may also prove use-
ful in solid organ transplantation applications.
The suppressive potency of allo-specific Treg can be assessed
in vitro by suppression assays (17–20). Some studies have also tried
to link the function and/or specificity of Treg to the expression of
coinhibitory markers, namely CTLA-4 (21) and PD-1 (22), and T
cell activation markers, such as HLA-DR (23), CD39 (24), and
CD40-L and 4-1BB (25). Nevertheless, a comprehensive descrip-
tion of allo-specific Treg function and phenotype is still lacking.
The present work provides an in-depth characteriza-
tion of expanded allo-specific Treg function and pheno-
type while establishing an expansion protocol that can be
easily translated into a clinical setting. Treg were expand-
ed in the presence of allogeneic monocyte-derived dendrit-
ic cells (moDC) using serum-free medium, with low or
intermediate concentrations of IL-2. The ability of allo-
specific Treg to suppress the proliferation of conventional
CD4 T cells (Tcon) and CD8 T cells was assessed using al-
logeneic moDC with distinct HLA profiles as stimulators.
In parallel, the mechanisms involved in the suppression of
responses to these distinct stimulators, particularly the
need for cell–cell contact, were investigated. To thoroughly
characterize the phenotypic profile of fresh and expanded Treg
(eTreg), an unbiased analysis of flow cytometry data was per-
formed using multidimensional visualization techniques. We
found that suppression by allo-specific Treg is contact depen-
dent and seems to be HLA specific.
MATERIALS AND METHODS
PBMC isolation and genotyping
Buffy coats of healthy donors were provided by the local blood
bank (Instituto Português do Sangue e Transplantaç~ao, Lisboa)
with the approval of the Ethics Committee of the Lisbon Aca-
demic Medical Centre. PBMCs were isolated by Ficoll Paque
PLUS (GE Healthcare) density gradient. Genomic DNA was
isolated with NZY Blood gDNA Isolation Kit (NZYTech) before
high-resolution genotyping at Instituto Português do Sangue e
Transplantaç~ao.
Flow cytometry staining
Cells were stained with the following anti-human monoclonal
Abs: CD3 (OKT3), CD19 (HIB19), and CD56 (TULY45) FITC;
CD3 (OKT3) PerCP-Cy5.5; CD86 (IT2.2) PerCPe710; CD4
(RPA-T4) APC; HLA-DR (LN3), CD8a (SK1) APCe780, and
Fixable Viability Dye e506 (eBioscience); CD14 (MuP9) V450,
CD11c (B-ly6) APC, CD127 (HIL-7R-M21) PE-Cy7, CD279
(EH12) BV605, CD152 (BNI3) PE-CF594, and CD39 (Tu66)
BV650 (BD Biosciences); CD4 (RPA-T4) BV785, CD137 (4B4-1)
APC, and CD154 (24–31) BV711 (BioLegend); and CD25 (2A3)
PE (StemCell).
Intracellular staining for FOXP3 (PCH101) e450 (eBio-
science), IL-2 (MQ1-17H12) APC, IL-10 (JES3-9D7) Alexa-Fluor
488 (BioLegend), and IL-4 (8D4-8) PE (BD Biosciences) was
performed using fixation/permeabilization reagents from eBio-
science. Data were analyzed using FlowJo10.
Differentiation of moDC
Monocytes isolated with EasySep Human CD14 Positive
Selection Kit II (StemCell) were cultured in X-Vivo 15
supplemented with L-glutamine (Lonza), 100 U/ml peni-
cillin, 100 mg/ml streptomycin (Invitrogen), IL-4 (40 ng/
ml), and GM-CSF (50 ng/ml; Peprotech) at 37C and 5%
CO2. Fresh medium was added on day 3. At day 5, differ-
entiated moDC were activated for 48 h with IL-1b (10 ng/
ml), IL-6 (10 ng/ml), TNF-a (20 ng/ml, Peprotech), and
PGE2 (1 mg/ml; Tocris Bioscience). Mature moDC were
typically CD14CD11c1CD8621HLADR21CD801CD831, as
described previously (18).
In vitro expansion of Treg
CD4 T cells were isolated using EasySep Human CD4
Positive Selection Kit II (StemCell) and labeled with 0.5
mM CellTrace CFSE Cell Proliferation Kit (Invitrogen).
Treg (CFSE1CD31CD41CD25highCD127low) and Tcon
(CFSE1CD31CD41CD25) were then sorted on a BD
FACSAria Fusion. Purity was $99% for both populations.
Treg (75  103 per well) were cocultured with irradiated al-
logeneic moDC (30 Gy) from HLA-mismatched donors at a
Treg/moDC ratio of 4:1 in 96-well plates. Culture medium was
TexMACS (Miltenyi Biotec) with recombinant human IL-2 (10
or 100 U/ml; R&D Systems), IL-15 (10 ng/ml; R&D Systems),
















and rapamycin (100 ng/ml; Sigma-Aldrich). From day 7 on-
wards, culture medium was replenished every 2 d with Tex-
MACS supplemented with only IL-2, until cells were harvested
for functional assessment on day 14. As a control, sorted Tcon
were expanded in the same conditions as Treg, except that cul-
ture medium was TexMACS supplemented with only recombi-
nant human IL-2 (10 or 100 U/ml).
Suppression assays
Fresh Treg and Tcon were isolated with EasySep Human
CD41CD127lowCD251 Regulatory T Cell Isolation Kit, and
CD81 cells were isolated with EasySep Human CD8 Positive Se-
lection Kit II (StemCell), all from the same donor as eTreg. Puri-
fied Tcon or CD8 responders (Resp) were labeled with 2.5 mM
CellTrace Violet (CTV) Cell Proliferation Kit (Invitrogen). Fresh
or eTreg were titrated to indicated ratios of Treg/Resp in dupli-
cate on 96-well plates with 25  103 CTV-labeled Resp and irra-
diated moDC at a Resp/moDC ratio of 4:1. Wells without Treg
(0:1) were used as negative controls for suppression. Cells were
incubated 6 d in RPMI 1640 with 10% heat-inactivated human
AB serum (Sigma-Aldrich), 100 U/ml penicillin, 100 mg/ml
streptomycin, and 2 mM L-glutamine (Invitrogen), after which
cells were stained for CD3, CD4, and CD8 and acquired on BD
LSRFortessa X-20. For analysis, cells from suppression assay
wells were gated on a forward versus side scatter and then on
CD31CD81 or CD31CD8CD41 Resp. To exclude Treg from
the Tcon analysis, an additional gate was made on CTV ver-
sus CD4 plots to select CTV-labeled cells, excluding CTV
cells by comparison with wells containing only Treg or only
Tcon (Treg/Resp 0:1). Within CTV-labeled cells (Tcon or
CD8), a gate on unproliferated (CTV1) cells was defined us-
ing unstimulated Resp cells, and the frequency of proliferat-
ed Resp was determined by gating on cells with diluted
CTV labeling. Resp proliferation was calculated by normal-
izing the frequency of CTV Resp in the presence of Treg
to the frequency found in the absence of Treg.
Cytokine quantification by Multiplex
At the end of suppression assays, cytokine concentration was mea-
sured in supernatants using the MILLIPLEX MAP Human High
Sensitivity T Cell Panel (IFN-g, IL-2, IL-4, IL-5, IL-10, IL-12p70,
IL-17A, IL-23, TNF-a), the MILLIPLEX MAP Human Cytokine/
ChemokineMagnetic Bead Panel IV (IL-35), and theMILLIPLEX
MAP TGFb1 Magnetic Bead Single Plex Kit (Millipore). Samples
were acquired on a MAGPIX System (Luminex) and ana-
lyzed using the xPONENT software (Luminex).
Transwell suppression assays
Tcon (CD31CD41CD25) and CD8 (CD31CD4CD81) Resp
from the same donor as Treg were sorted on BD FACSAria Fu-
sion and labeled with CTV. A total of 5  104 Resp and 1.25 
104 irradiated moDC were cultured in duplicate in the bottom
chamber of 96-well Transwell plates. Irradiated moDC were
added to top and bottom chambers at a dendritic cell (DC)/T
cell ratio of 1:4. In the top chamber, eTreg were cultured alone
(1  104) or with Resp cells at Treg/Resp ratio of 1:5. In standard
suppression assay controls, eTreg (1  104) were cultured with
Resp in the bottom chamber, without cells in the top chamber.
At day 6, Resp proliferation was measured in bottom wells
on BD FACSAria Fusion. Cells from top chambers of Transwell
and from standard controls were restimulated for 4 h with Cell
Stimulation Cocktail (eBioscience) prior to intracellular cyto-
kine staining. Samples were acquired on BD LSRFortessa X-20.
For analysis, Resp were distinguished from Treg based on the
expression of CTV (similarly to previous suppression assays).
Cutoffs for cytokine secretion were based on cytokine expres-
sion in fluorescence-minus-one controls.
Multidimensional analysis of cytometry data
FlowSOM or k-means clustering algorithms were used to ana-
lyze flow cytometry data from three experimental replicates
from each condition, as described previously (26). Briefly, data
from each sample were manually compensated, gated on
CD31CD41 cells, and downsampled (DownSampleV3 plugin)
before being exported from FlowJo. The fcs files were then
concatenated to a single fcs file (flowCore package). FlowSOM-
based unsupervised analysis was then performed (27), in which
each cell was assigned to a node in a 5  5 grid, building a self-
organizing map (SOM) based on the expression of selected
markers (BuildSOM function). A minimum spanning tree of
the SOM was built and plotted (BuildMST function). Then,
data from each condition (three concatenated fcs files each)
were mapped to the same SOM (NewData function), and in-
dividual minimum spanning trees were built. For k-means
clustering, data in a single concatenated file were prepro-
cessed by transforming the fluorescence channels (28) (us-
ing the flowTrans function) and normalized by scaling.
The optimal number of clusters (5) was determined by plot-
ting sum of squares versus number of clusters, and then k-
means clustering was performed (kmeans function). Individ-
ual histograms were created for each marker, showing mean
expression for each cluster. Then, cells were labeled based on
their condition of origin to observe cluster distribution per
condition. Statistical analysis of the differences in frequency
of cells assigned to each cluster was performed using ANOVA.
Computational analysis was conducted using RStudio (version
1.2.5001, with R version 3.5.0) on a MacBook Pro running the
OS X Mojave 10.14.6 with a 2.6 GHz Intel Core i5 processor.
Statistical analysis
Statistical analysis was performed on GraphPad Prism 7.00
software using a confidence level of 0.95. The p values < 0.05
were considered significant. For comparisons between condi-
tions (e.g., different stimulators and conditions), Student paired
t tests with the Holm–Sidak method or Fisher least significant
difference test were used. For comparisons within the same
condition (e.g., different dilutions), two-way ANOVA was used,
with Dunnett multiple comparison corrections.

















Allo-specific Treg are highly suppressive
We sought to optimize an allo-specific Treg expansion protocol
that could potentially be translated to the clinic because most
GMP-suitable protocols focus on polyclonal Treg expansion
(29, 30). As one of the hindrances for clinical translation of cur-
rent protocols is the use of human serum (18, 31), we expanded
allo-specific Treg in serum-free conditions. First, fresh
CD251CD127low Treg were sorted from CFSE-labeled CD41
cells (Presort), resulting in a highly enriched population for
FOXP3 (Fig. 1A, 1B, presort versus fresh Treg). CFSE1 Treg
were cocultured for 14 d with moDC from an allogeneic donor,
henceforth referred to as original DC donor. To prevent the ex-
pansion of contaminating Tcon, rapamycin was added to the
culture media (32), along with IL-2 and IL-15 (19). After 14 d,
the frequency of proliferated Treg with different concentrations
of IL-2 was similar (Fig. 1C), although Treg fold expansion was
slightly higher with 100 U/ml of IL-2 (Fig. 1D).
To determine the suppressive potency of these eTreg, sup-
pression assays were performed with moDC from the original
DC donor as stimulators and Tcon (Fig. 1E, 1F) or CD81 (Fig.
1G, 1H) as Resp. When compared with control wells without
Treg (Treg/Resp 0:1), Tcon proliferation was significantly re-
duced by Treg expanded with 10 U/ml of IL-2 at a Treg/Resp
ratio of 1:10 (Fig. 1E). Interestingly, significant Tcon suppres-
sion was achieved by Treg expanded with 100 U/ml of IL-2 at
just 1:50 Treg/Resp (Fig. 1E). When compared with fresh Treg,
Treg expanded with 100 U/ml of IL-2 were significantly more
suppressive of Tcon (Fig. 1F, p = 0.045). As for CD8 Resp, pro-
liferation was significantly suppressed by eTreg from either ex-
pansion condition at a Treg/Resp ratio of just 1:50 (Fig. 1G).
Furthermore, both types of eTreg were significantly more sup-
pressive than fresh Treg (Fig. 1H, p = 0.037 and p < 0.001 for
10 U/ml and 100 U/ml of IL-2 eTreg, respectively). Thus, our
serum-free protocol for allo-specific Treg expansion yielded
highly suppressive Treg.
Allo-specific Treg and Tcon are phenotypically distinct
The expression of CD25, CD127, and FOXP3 was analyzed by
flow cytometry in both Treg and Tcon before expansion (fresh
Treg and fresh Tcon, Fig. 2A) and then compared with the phe-
notype of these cells after expansion with different concentra-
tions of IL-2 (Fig. 2B, 2C). eTreg had higher expression of CD25,
CD127, and FOXP3 than fresh Treg (Fig. 2B). CD25 and FOXP3
expression in expanded Tcon was also increased in both settings
but more so after expansion with 100 U/ml of IL-2 (Fig. 2C).
To better characterize the phenotype of eTreg and Tcon,
we analyzed PD-1, CTLA-4, CD39, HLA-DR, CD40L, and 4-
1BB expression with the multidimensional visualization tech-
nique FlowSOM (27). Briefly, using concatenated data from all
samples being compared, a pseudo-randomized algorithm allo-
cates each cell to a node on a user-defined 5  5 grid, based on
its expression of all markers. The output is a minimum
spanning tree with 25 nodes distributed spatially according to
similarities between nodes. Then, data from each individual
sample are projected onto the same minimum spanning tree to
visualize its phenotype.
As the starting Treg population was mostly pure (Fig. 1B)
and there was high potency of suppression by eTreg (Fig. 1E,
1H), the presence of contaminating Tcon within allo-specific
Treg was unlikely. Nevertheless, as the phenotype of expanded
Tcon might resemble that of Treg, we compared Treg and
Tcon after expansion with 100 U/ml of IL-2. Interestingly, ex-
panded Tcon and eTreg with the highest expression of activa-
tion markers (CD39, HLA-DR, CD40-L, and 4-1BB) were
allocated to different nodes (Fig. 2D, 2E, orange arrow in Tcon
and black arrow in Treg). Importantly, this visual representa-
tion of data analyzed in an unbiased way would not be possible
through conventional flow cytometry data analysis.
Overall, this analysis indicates that allo-specific Treg were
mostly free from activated Tcon, as there was virtually no over-
lap between the minimum spanning trees of expanded Tcon
and eTreg.
IL-2 concentration during Treg expansion affects
suppressive potency
To verify the specificity of allo-specific Treg, the suppression of
responses to moDC from the same donor used for expansion
(original DC) was compared with the potency of suppression of
responses to stimulators from a fully HLA-mismatched third-
party donor (mismatch 3P). Proliferation in the presence of
Treg was normalized to that found in control wells without
Treg (0:1 Treg/Resp). In all settings, Resp were derived from
the same donor as Treg.
Treg expanded with 10 U/ml of IL-2 did not suppress
Tcon proliferation when mismatch 3P stimulators were used
(Fig. 3A). In fact, at high Treg/Resp ratios, Tcon proliferation
was significantly higher with mismatch 3P than with the
original DC stimulators. Although CD8 proliferation was sup-
pressed by Treg expanded with 10 U/ml of IL-2 in the pres-
ence of mismatch 3P stimulators, proliferation to original DC
stimulators appeared more suppressed (Fig. 3B). In suppres-
sion assays with Treg expanded with 100 U/ml of IL-2, Tcon
and CD8 proliferation also seemed higher with mismatch 3P
than with original DC stimulators (Fig. 3C, 3D), indicating
that the suppressive activity of allo-specific Treg was specific
toward the original DC stimulator.
These results showed allo-specific Treg were capable of
both allo-specific and nonspecific suppression and that both
types of suppression were enhanced when higher IL-2 concen-
trations were used during Treg expansion.
Allo-specific Treg recognize cognate HLA alleles in
third-party stimulators
Next, we wanted to assess if these allo-specific Treg would be
more suppressive of responses to third-party donors if there
















FIGURE 1. Expansion of allo-specific Treg with 10 U/ml or 100 U/ml of IL-2 and respective potency of suppression of Tcon and CD8 Resp.
(A and B) Expression of CD25 and FOXP3 in CD41 cells used for sorting (A) and in fresh Treg after sorting (B). (C and D) Proliferation (C) and fold ex-
pansion (D) of Treg. (E) Normalized proliferation of Tcon in response to moDC from the original DC donor, in the presence of Treg expanded with
10 U/ml of IL-2 (black circles) or 100 U/ml of IL-2 (open circles) at several Treg/Resp ratios. (F) Degree of Tcon suppression by fresh Treg (black
bar), Treg expanded with 10 U/ml of IL-2 (light gray bar), and Treg expanded with 100 U/ml of IL-2 (dark gray bar) at a Treg/Resp ratio of 1:5. (G)
Normalized proliferation of CD8 cells in response to moDC from the original DC donor, in the presence of Treg expanded with 10 U/ml of IL-2
(black circles) or 100 U/ml of IL-2 (open circles) at indicated Treg/Resp ratios. (H) Degree of CD8 suppression by fresh Treg (black bar), Treg ex-
panded with 10 U/ml of IL-2 (light gray bar), and Treg expanded with 100 U/ml of IL-2 (dark gray bar) at a Treg/Resp ratio of 1:5. Data were ob-
tained from three independent experiments. (C–H) Values for average and SD are shown. Statistical analysis of differences between dilutions was
performed with one-way ANOVA, and differences between conditions were evaluated with multiple t tests, by the Holm–Sidak method. Statistical
significance was assumed for p < 0.05 (*,#p < 0.05, **,##p < 0.005, ***,###p < 0.0005, ****,####p < 0.0001).
















were partial HLA matches between those donors and either
the original DC donor or the Treg donor.
Thus, we performed suppression assays using, as stimulators,
moDC from third-party donors either partially matched to the
original DC donor in HLA class I and HLA class II (DC-match
3P) or partially matched to the Treg donor in HLA class II
(Treg-match 3P). Stimulators from the original DC and mis-
match 3P were used as controls for specific and nonspecific
suppression, respectively. In matched donors, the degree of
matching per class ranged from two to four out of six se-
quenced alleles. HLA high-resolution genotyping results
can be found in Supplemental Table I.
In conditions with DC-match 3P and Treg-match 3P
stimulators, Tcon proliferation was significantly suppressed
by Treg expanded with either 10 U/ml or 100 U/ml of IL-2,
when compared with the control without Treg (0:1 Treg/
Resp; Supplemental Fig. 1A, 1B). When comparing the de-
gree of proliferation detected with different stimulators at a
Treg/Resp ratio of 1:10, Tcon responses to partially matched
third-party stimulators seemed more suppressed than those
to mismatch 3P (Fig. 4A). Interestingly, with 100 U/ml of
IL-2 eTreg as suppressors, Tcon responses to DC-match 3P,
but not to Tregmatch 3P, were more suppressed than those to
mismatch 3P (Fig. 4A, right).
With CD8 Resp, there was statistically significant suppression
of proliferation with all stimulators by 10 U/ml and 100 U/ml of
IL-2 eTreg when compared with the control without Treg
(Supplemental Fig. 1C, 1D). However, when comparing stimula-
tors at a Treg/Resp ratio of 1:10, responses to DC-match 3P were
more suppressed than those to mismatch 3P (Fig. 4B), as seen
with Tcon Resp. Overall, Tcon and CD8 proliferation seemed
most suppressed with original DC or DC-match 3P stimulators
and least suppressed with Treg-match 3P and mismatch 3P, sug-
gesting that allo-specific Treg are not only specific toward the
stimulator used for their expansion but can also detect cognate
HLA alleles in third-party stimulators, particularly those found
in the original DC donor.
Because Treg expanded with higher concentrations of
IL-2 seemed more potent in both specific and nonspecific
settings, subsequent assays were focused on allo-specific
Treg expanded with 100 U/ml of IL-2. To ascertain if the
presence of Treg affected cytokine concentrations during
the suppression assay, the levels of Th1 (Fig. 4C–E) and
Th2 (Fig. 4F, 4G) cytokines were measured in the super-
natants. Control wells without Treg (0:1 Treg/Resp) had
quantifiable concentrations of IL-2, TNF-a, and IFN-g in
their supernatant (Fig. 4C–E), yet these cytokines were
nearly undetectable in wells with allo-specific Treg at a
1:5 Treg/Resp ratio. Interestingly, similar trends were
found for IL-2 and IFN-g with CD8 Resp, albeit at much
lower ranges, because cytokine secretion by CD8 Resp
alone was very low (Supplemental Fig. 1E, 1F). Further-
more, IL-5 (Fig. 4F) and IL-4 (Fig. 4G) were only de-
tected in the supernatant of control wells with Tcon (0:1
Treg/Resp), but only IL-5 seemed to be affected by the
presence of allo-specific Treg (Fig. 4F). Of note, we also
measured the concentration of IL-10 and TGF-b, usually
associated with Treg function, but we did not find their
concentrations to be increased by the presence of allo-
specific Treg (Supplemental Fig. 1G, 1H). Although it can-
not be excluded that Treg produce IL-10, this observation
suggests that other mechanisms may be driving suppres-
sion by allo-specific Treg.
The suppressive mechanisms employed by Treg depend on
both Resp and DC. Thus, we compared the degree of suppres-
sion achieved by Treg to the expression of CD86 in each DC
population at the beginning of suppression assays. Interestingly,
we found that higher initial CD86 median fluorescence intensi-
ty was strongly correlated to lower suppression of both Tcon
and CD8 (Supplemental Fig 2A, 2B). Because it has been shown
that CTLA-4 may capture CD86 from the surface of DC, we
hypothesized that the association of lower suppression with
higher CD86 expression could be a result of limiting levels of
CTLA-4 on Treg. However, CTLA-4 blockade did not impair
suppression by Treg (Supplemental Fig 2C, 2D). Moreover, re-
gardless of the CD86 expression, responses to the original DC
donors were always the most suppressed, indicating that HLA
specificity is more relevant for Treg suppression than CD86
levels on moDC.
In summary, suppression of Resp proliferation by allo-spe-
cific Treg seemed most influenced by the HLA profile of the
stimulators, suggesting that allo-specific Treg are HLA specific
in their suppression.
Specific suppression by allo-specific Treg requires cell–cell
contact
To assess whether T–T cell contact was required for sup-
pression by allo-specific Treg, transwell experiments were
performed in which Treg were cultured in the top chamber
alone or with Resp at a 1:5 Treg/Resp ratio. CTV-labeled
Tcon or CD8 Resp were cultured in the bottom chamber. In
both settings, cells in top and bottom chambers were stimu-
lated by either original or mismatch 3P moDC. Standard
suppression assays, with cell–cell contact between Resp and
allo-specific Treg, were used as a positive control. HLA
high-resolution genotyping of all donors is available in
Supplemental Table II. To assess the importance of contact
for allo-specific Treg function, fold suppression of Resp
proliferation in bottom chambers was evaluated, by normal-
izing suppression in top chambers to that found in equiva-
lent conditions of standard suppression assays.
With moDC from the original DC donor as stimulators, sup-
pression of Tcon was significantly lowered by the lack of con-
tact between Treg and Resp in the bottom well, when
compared with the control (Fig. 5A, black bars). In this setting,
the presence of Tcon together with allo-specific Treg in the top
chamber (Top well 1:5 Treg/Tcon) did not increase the sup-
pression of Resp cells in the bottom chamber, when compared
with Treg alone in the top well, suggesting that allo-specific


















FIGURE 2. Phenotype of eTreg and expanded Tcon samples.
(A–C) Dot plots depicting the expression of CD25 and CD127 (top) and CD25 and FOXP3 (bottom) on Treg and Tcon before expansion (A), on Treg
before and after expansion with 10 or 100 U/ml of IL-2 (B), and on Tcon before and after expansion with 10 or 100 U/ml of (Continued)
















Treg do not release suppressive cytokines nor stimulate Resp to
produce suppressive factors (Fig. 5A, black bars). Similar results
were observed with CD8 Resp, as significantly lower fold sup-
pression was found when allo-specific Treg were cultured
alone in the top well than in control wells with Resp (Fig. 5B,
black bars).
Furthermore, fold suppression in the absence of contact
was higher in conditions with mismatch 3P than with original
DC stimulators, being closer to the suppression found in con-
trols with contact (dotted line), suggesting that the suppression
of nonspecific responses was only partially inhibited by the lack
of contact between allo-specific Treg and Resp in the bottom
well (Fig. 5A, 5B; gray bars). Interestingly, the presence of Resp
together with allo-specific Treg in the top well seemed to en-
hance the suppression of CD8 Resp, when compared with the
control (Top well 1:5 Treg/CD8, Fig. 5B). Overall, these results
suggest that distinct mechanisms of suppression could be at
play in specific and nonspecific settings.
To ascertain if allo-specific Treg modulate the maxi-
mal capacity for cytokine production in Resp, we
IL-2(C). Data from one representative experiment are shown. (D and E) Minimum spanning trees of the phenotype expressed by Tcon expanded
with 100 U/ml of IL-2 (D) and by Treg expanded with 100 U/ml of IL-2 (E). The diameter of each node is proportional to the total number of cells
allocated to it, and each node displays the relative intensity of all markers on that node. Nodes with highest expression of activation markers are
signaled by an orange arrow for Tcon and a black arrow for Treg. The legend for each marker can be found in a pie chart. Each phenotype shows
cumulative data from three independent experiments, after down sampling.
FIGURE 3. Specificity of suppression of different Resp by Treg expanded with 10 U/ml or 100 U/ml of IL-2.
(A and B) Proliferation of Tcon (A) or CD8 (B) in the presence of Treg expanded with 10 U/ml of IL-2 at several Treg/Resp ratios, in response to
moDC from the original DC donor (black circles) or from a mismatch 3P (gray triangles). (C and D) Proliferation of Tcon (C) or CD8 (D) in the pres-
ence of Treg expanded with 100 U/ml of IL-2 at several Treg/Resp ratios, in response to moDC from the original DC donor (open circles with cross)
or from a mismatch 3P (gray inverted triangles). Data were obtained from four independent experiments. Statistical analysis of differences between
dilutions was performed with one-way ANOVA, and differences between conditions were evaluated with multiple t tests, by the Holm–Sidak meth-
od. Statistical significance was assumed when p < 0.05 (*p < 0.05, **p < 0.005, ***p < 0.0005). Error bars show SD.
















restimulated the cells with PMA and ionomycin at the
end of suppression assays and measured the frequency of
IL-21 and IL-41 Resp. These frequencies were then nor-
malized to those found in control wells without Treg
(control 0:1). The normalized frequency of IL-21 Tcon
and CD8 was similar with original DC or mismatch 3P
stimulators and seemed unaltered by culture with allo-
specific Treg (Fig. 5C, 5D). As for IL-4, the capability of
FIGURE 4. Suppression of proliferation and cytokine secretion by allo-specific Treg in the presence of moDC from differently HLA-mismatched
donors.
(A and B) Average of normalized proliferation of Tcon (A) and CD8 (B) in the presence of allo-specific Treg expanded with 10 U/ml of IL-2 (10 U/ml
of IL-2 eTreg, left) or 100 U/ml of IL-2 (100 U/ml of IL-2 eTreg, right) at a Treg/Resp ratio of 1:10. Stimulators are moDC from the donor used in
Treg expansion (original DC donor; black circles), DC-match 3P (gray diamonds), Treg-match 3P (dark gray squares), or mismatch 3P (gray trian-
gles). (C–G) Concentration of IL-2 (C), TNF-a (D), IFN-g (E), IL-5 (F), and IL-4 (G) measured by Multiplex in the supernatant of suppression assay
wells without Treg (0:1 Treg/Resp; black circles) or with Treg expanded with 100 U/ml of IL-2 at a Treg/Resp ratio of 1:5 (1:5 Treg/Resp; open dia-
monds). Data were obtained from three to four independent experiments. Statistical differences were evaluated with multiple t tests, by the Holm–
Sidak method, with p < 0.05 (*p < 0.05, **p < 0.005). Error bars show SD.
















Tcon and CD8 to produce IL-4 upon restimulation was
maintained or slightly lowered after culture with allo-
specific Treg and original DC stimulators (Fig. 5E, 5F).
Surprisingly, this capability seemed increased after cul-
ture with allo-specific Treg if the stimulators were mis-
match 3P (Fig. 5E, 5F), suggesting culture with allo-
specific Treg may modulate the cytokine production po-
tential of Resp.
Overall, we found that the mechanisms of suppression
by allo-specific Treg were dependent on their specificity
toward stimulators, as suppression of responses to the
same stimuli used during expansion was strictly contact
dependent, whereas suppression of responses to unknown
stimuli was partially independent of contact.
Allo-specific Treg express multiple phenotypes
To thoroughly characterize the phenotype of allo-specific
Treg subsets after expansion, multidimensional visualiza-
tion techniques were applied based on the expression of
CTLA-4, PD-1, CD39, HLA-DR, 4-1BB, and CD40-L. By
applying k-means clustering to fresh and allo-specific
Treg samples, five clusters could be identified (Fig. 6A).
Cluster phenotypes are described in histograms for each
marker (Fig. 6B).
Interestingly, we found that some phenotypes were
expressed mostly by fresh Treg, whereas others were
only expressed by allo-specific Treg (Fig. 6A). Fresh Treg
expressed cluster 2 (CTLA-4CD40-L4-1BBPD-11) and
cluster 4 (CTLA-41CD40-L14-1BB1PD-1) phenotypes
FIGURE 5. Potency and mechanisms of suppression by allo-specific Treg in cognate and noncognate settings.
(A and B) Fold suppression of proliferation of Tcon (A) and CD8 (B) cultured in the bottom chamber, when Treg expanded with 100 U/ml of IL-2
were cultured in the top chamber of Transwell plates alone (bars on the left) or with Resp, at a Treg/Resp ratio of 1:5 (bars on the right). Black bars
show results when original DC were used as stimulators in top and bottom chambers, and gray bars show results for mismatch 3P. Data were nor-
malized to the suppression found when both Resp and Treg were cultured in the bottom chamber (standard suppression assay controls), repre-
sented by the dotted line. (C and D) Fold change in the frequency of IL-2– (C) and IL-4– (D) producing Tcon (left) or CD8 (right) upon
restimulation with PMA and ionomycin, after culture with Treg expanded with 100 U/ml of IL-2 at a Treg/Resp ratio of 1:5 in the bottom chamber
of standard suppression assay controls. Data were normalized to controls without Treg (0:1), represented by the dotted line. Data were obtained
from two to three independent experiments. Statistical analysis of differences in Resp proliferation or cytokine concentration was evaluated with
multiple t tests, by the Holm–Sidak method. Statistical significance was assumed when p < 0.05. The asterisk (*) represents statistically significant
differences between a condition and the control with p < 0.05.
















FIGURE 6. Phenotype of fresh and eTreg.
(A) The k-means clustering analysis. The frequency of cells allocated to each cluster is represented on polar plots (top) or bar plots (bottom). The
radius of a cluster or the height of a bar represents the mean percentage of cells allocated to that cluster, and the error bar represents SD. Statisti-
cal analysis was performed by multiple t tests on R Stats package. (B) Histograms with the relative expression of each marker (Continued)
















(Fig. 6A), which had converse expression of CTLA-4,
CD40-L, 4-1BB, and PD-1 yet were similar in their low
expression of HLA-DR and relatively low CD39, a typical
phenotype of ex vivo cells.
After expansion, allo-specific Treg had a similar frequency
of cells expressing cluster 4 to fresh Treg, yet cluster 2 was sig-
nificantly reduced. In addition to cluster 4, allo-specific Treg
expressed three unique subsets with distinct levels of PD-1,
CD39, and HLA-DR: clusters 1, 3, and 5. Clusters 1 (PD-1low
CD391HLA-DR1) and 3 (PD-11CD39HLA-DR1) had con-
verse expression of PD-1 and CD39, and when compared with
cluster 4, cluster 1 (PD-1low CD391HLA-DR1) and cluster 3
(PD-11CD39HLA-DR1) had higher expression of HLA-DR,
CD40-L, and 4-1BB, which was expected after culture. In con-
trast, cluster 5 (PD-1low CD39lowHLA-DRlow) had low expres-
sion of all activation markers.
Similar results were found using FlowSOM, as some nodes
comprised mostly cells from fresh Treg samples (Fig. 6C, black
arrow) and others comprised cells from allo-specific Treg sam-
ples (Fig. 6C, red arrows). Overall, the phenotype of fresh Treg
(Fig. 6D) was very different from that of eTreg (Fig. 6E, 6F).
Particularly, allo-specific Treg had more cells allocated to nodes
representing a more-activated phenotype, as had been detected
by k-means clustering analysis, whereas fresh Treg had more
cells allocated to nodes with low expression of most markers
(Fig. 6D–F). Furthermore, we were able to identify groups of
nodes with subphenotypes similar to the clusters defined by k-
means clustering and label them accordingly (Fig. 6D–F). Of
note, the concentration of IL-2 during expansion did not seem
to affect the range of phenotypes expressed by Treg, just the
frequency of cells allocated to each cluster.
Ultimately, using these innovative techniques for multidi-
mensional visualization of flow cytometry data, five unique
Treg subsets could be defined. Particularly, ex vivo Treg ex-
pressed two major phenotypes, one of which was no longer ex-
pressed after expansion. The other subset was expressed by
allo-specific Treg, together with three other activated subsets,
distinguishable through the combined expression of PD-1,
CD39, and HLA-DR.
DISCUSSION
The present work demonstrates that allo-specific Treg can be
expanded in serum-free conditions with low and intermediate
IL-2 concentrations, without compromising the potency or spe-
cificity of suppression. To our knowledge, this is also the first
report of eTreg displaying distinct mechanisms of suppression
in specific and nonspecific settings.
Treg expanded with our serum-free expansion protocol
were more-potent suppressors of Tcon and CD8 proliferation
than fresh Treg, as has been described for Treg expanded in
the presence of human serum (19, 33). Significant suppression
of responses to the stimulator used during expansion was con-
sistently found at Treg/Resp ratios of 1:10 and even at Treg/
Resp ratios of 1:50, whereas suppression by polyclonally eTreg
has been shown to require Treg/Resp ratios of at least 1:2 (34,
35). Thus, allo-specific Treg were found to be more potent than
polyclonally eTreg. Allo-specific Treg expansion is usually car-
ried out with low IL-2 concentration to prevent polyclonal
Treg expansion and the recruitment of non-Treg (19). Howev-
er, there are also reports of allo-specific Treg being expanded
with high IL-2 concentration (10, 11, 36). In our study, interme-
diate IL-2 concentration during allo-specific Treg expansion
seemed to increase the potency of Tcon suppression.
Treg with a particular specificity have been shown to also
suppress nonspecific responses (37). Nevertheless, Treg are
usually considered specific when they are more-potent suppres-
sors of responses to their original stimulator than to fully mis-
matched donors (10, 19, 38–40) or to mitogenic beads (25). In
this work, we show that allo-specific Treg are always more
suppressive of responses to their original stimulators. However,
there is still some nonspecific suppression, particularly when
CD8 cells are used as Resp. Based on the cytokine quantifica-
tion studies performed in this study, it seems that the suppres-
sion mechanisms may be distinct for CD4 and CD8 T cells. In
fact, we show that modulation of cytokine production may be
one of the mechanisms by which Treg suppress Resp, particu-
larly Tcon. Furthermore, the downregulation of the production
of cytokines, such as IL-2, TNF-a, and IFN-g, seems to have a
higher impact on the suppression of Tcon responses than on
that of CD8.
The Ag specificity in allo-specific Treg is usually unknown.
In fact, it is expectable that they are specific for a plethora of
Ags, rather than to a particular one. Until now, it had not been
ascertained whether allo-specific Treg could suppress re-
sponses to partially matched donors and to what extent. We
found that, when a third-party donor is partially HLA matched
to the DC donor used in expansion, there is similar suppression
of responses to both stimulators, suggesting that allo-specific
within clusters defined by k-means clustering. (C–F) FlowSOM analysis of phenotypes expressed by Treg before and after expansion. (C) Minimum
spanning tree of all analyzed samples. The diameter of each node is proportional to the total number of cells attributed to it, and each node dis-
plays the frequency of cells from each sample allocated to that node. Black arrow indicates nodes comprising mostly cells from fresh Treg, where-
as red arrows indicate nodes comprising predominantly expanded cells. (D) Minimum spanning tree of fresh Treg, (E) Treg expanded with 10 U/ml
of IL-2, and (F) Treg expanded with 100 U/ml of IL-2. Groups of nodes with similar phenotype to the clusters found by k-means clustering were
identified: cluster 1 is represented by a blue circle, cluster 2 is represented by a green circle, cluster 3 is represented by an orange circle, cluster 4 is
represented by a yellow circle, and cluster 5 is represented by a gray circle. Each node displays the relative intensity of all markers on that node,
and the legend for markers can be found in a pie chart in the lower right corner.
















Treg can recognize cognate HLA alleles. This may prove rele-
vant for future development of Treg therapies, as in cases in
which patient-derived APC are not available, donor-derived
Treg could be expanded with APC from donors partially
matched to the patient.
In this article, we show, to our knowledge for the first time,
that different mechanisms are involved in suppression of re-
sponses to specific and nonspecific stimuli. We showed that
suppression of responses to the original expansion stimulators
was strictly contact dependent, whereas there was partial con-
tact-independent suppression of responses to mismatch 3P. In
fact, even when allo-specific Treg were cultured with Resp and
stimulated by the original expansion DC, it did not seem to re-
sult in the production of suppressive cytokines capable of con-
tact-independent suppression.
It is of relevance that the suppression mediated by allo-spe-
cific Treg is strictly contact dependent and apparently HLA spe-
cific, as this finding may have important clinical implications. In
the setting of allo-HSCT, the main potential use of these cells
would be in the prevention and/or treatment of GvHD. Going
forward, we plan to generate donor-derived recipient-specific
Treg, using real-life donor/recipient allo-HSCT samples. Our ul-
timate goal is to ascertain that donor-derived allo-specific Treg
suppress responses against normal recipient-derived DC but not
against recipient-derived DC presenting leukemia Ags. Thus, the
current study is an essential first endeavor, to our knowledge,
toward generating donor-derived allo-specific Treg that sup-
press GvHD while sparing GVL responses.
IL-10 is reportedly involved in contact-independent sup-
pression by Treg (23). However, we did not find IL-10 concen-
tration to be increased by the presence of allo-specific Treg in
the supernatants of suppression assays (Supplemental Fig. 1G,
1H) nor did we detect the production of IL-10 by Treg or Resp
upon restimulation with PMA and ionomycin at the end of sup-
pression assays (data not shown). Thus, suppression seemed in-
dependent of IL-10, which is in accordance with previous
reports (33, 41), and suggests that other mechanisms may be at
play in suppression by allo-specific Treg.
Importantly, allo-specific Treg seemed to modulate the ca-
pability for IL-4 production in Resp, possibly eschewing them
to express an anti-inflammatory phenotype. The induction of
IL-4 secretion in Tcon has been described by others in sup-
pression assays using mitogenic beads (23, 42), but the observa-
tion that the capability to produce IL-4 seems increased only in
nonspecific suppression settings constitutes a to our knowledge
novel finding. It would be interesting to block IL-4 in suppres-
sion assays, but, as Ag-specific Treg have been shown to rely
on IL-4 signaling (43), this could also impair Treg function.
Looking into the effect of DC phenotype in suppression by
Treg, we found higher CD86 expression on moDC was corre-
lated to lower suppression. Because CTLA-4 blockade did not
impair suppression by Treg, this correlation does not seem de-
rived from a limiting amount of CTLA-4 on Treg surface. One
possibility is that higher CD86 expression allows for Resp to es-
cape Treg-mediated suppression, as it has been shown that
costimulation with CD80 and CD86 allowed for Th cells to
evade suppression in the presence of high Ag dose (44).
Finally, HLA-DR (23), CD39 (24, 45), and 4-1BB (25) have
been individually linked to the suppressive ability of Treg.
However, no report has described the simultaneous expression
of these markers on Treg subsets. After multidimensional anal-
ysis of ex vivo and eTreg, our data suggest that the coexpres-
sion of HLA-DR, CD39, and PD-1 can identify Treg subsets that
might share not only the same phenotype but possibly also sim-
ilar functional mechanisms.
Overall, our data show that Treg expanded in serum-free
conditions with allogeneic moDC are allo-specific and may rec-
ognize matched HLA alleles in third-party donors. Furthermore,
we provide new insights on the mechanisms of suppression dis-
played by allo-specific Treg, as specific stimulation prompts
contact-dependent suppression, whereas nonspecific stimuli
elicit both contact-dependent and -independent suppression.
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